HRAS encodes a small GTPase that functions as a critical signaling hub in cell proliferation and differentiation 1. The protein cycles between inactive GDP-bound and active GTP-bound states, possessing intrinsic GTPase activity that regulates signal transduction 2. HRAS translocates signaling molecules to the plasma membrane to activate multiple downstream pathways controlling cell growth, differentiation, apoptosis, and actin cytoskeleton organization 1. It acts as a pathway branchpoint, orchestrating diverse cellular functions including cell migration and neuronal activity 1. HRAS mutations drive tumorigenesis in specific contexts. Activating HRAS mutations are associated with epithelial-myoepithelial carcinoma of salivary glands 3, penile cancer 4, and thyroid cancer 5. Notably, high HRAS transcript expression paradoxically correlates with superior overall survival in colorectal cancer stages II-III, particularly when KRAS mutations are absent 6. Germline HRAS mutations cause Costello syndrome, a developmental disorder featuring craniofacial abnormalities, cardiac defects, developmental delay, and increased cancer predisposition 5. In rhabdomyosarcoma, oncogenic HRAS expression induces senescence in alveolar variants through RB pathway activation and p16/p21 upregulation, suggesting context-dependent effects 7.